Verteporfin Photodynamic Therapy + Ranibizumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polypoidal Choroidal Vasculopathy
Conditions
Polypoidal Choroidal Vasculopathy
Trial Timeline
Apr 1, 2008 → —
NCT ID
NCT00674323About Verteporfin Photodynamic Therapy + Ranibizumab
Verteporfin Photodynamic Therapy + Ranibizumab is a approved stage product being developed by Novartis for Polypoidal Choroidal Vasculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00674323. Target conditions include Polypoidal Choroidal Vasculopathy.
What happened to similar drugs?
4 of 6 similar drugs in Polypoidal Choroidal Vasculopathy were approved
Approved (4) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00674323 | Approved | Completed |
Competing Products
9 competing products in Polypoidal Choroidal Vasculopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 27 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 35 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 40 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 43 |
| Rescue Intravitreal Aflibercept Injection | Regeneron Pharmaceuticals | Approved | 39 |
| Aflibercept Intravitreous Injection | Bayer | Approved | 47 |
| aflibercept 8 mg | Bayer | Phase 3 | 44 |
| aflibercept | Bayer | Approved | 40 |
| ranibizumab intravitreal injection | Pacific Biosciences | Phase 1 | 19 |